Analysts Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) PT at $169.20

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-three brokerages that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $166.90.

Several research analysts recently issued reports on the company. William Blair restated an "outperform" rating on shares of Neurocrine Biosciences in a research report on Friday. StockNews.com upgraded Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Monday. Barclays boosted their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an "overweight" rating in a research note on Monday, December 23rd. Wedbush decreased their price target on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating on the stock in a research note on Friday. Finally, Guggenheim lowered their price target on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating for the company in a report on Monday.

Neurocrine Biosciences Price Performance

Shares of NBIX stock traded down $2.34 during trading hours on Friday, reaching $116.47. 2,289,398 shares of the company's stock were exchanged, compared to its average volume of 1,299,225. Neurocrine Biosciences has a 1 year low of $110.95 and a 1 year high of $157.98. The company has a market cap of $11.79 billion, a P/E ratio of 35.40 and a beta of 0.33. The company's 50 day moving average is $138.81 and its two-hundred day moving average is $131.42.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. As a group, analysts predict that Neurocrine Biosciences will post 6.53 EPS for the current fiscal year.

Insider Activity

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 272 shares of the business's stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the transaction, the insider now owns 2,507 shares of the company's stock, valued at approximately $346,216.70. The trade was a 9.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kyle Gano sold 65,000 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the transaction, the chief executive officer now owns 135,392 shares of the company's stock, valued at approximately $19,157,968. This represents a 32.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 222,693 shares of company stock valued at $32,718,279 over the last ninety days. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Cetera Investment Advisers raised its holdings in Neurocrine Biosciences by 7.9% in the 2nd quarter. Cetera Investment Advisers now owns 7,112 shares of the company's stock valued at $979,000 after buying an additional 519 shares during the last quarter. Sanctuary Advisors LLC acquired a new stake in Neurocrine Biosciences during the second quarter worth approximately $510,000. GAMMA Investing LLC increased its stake in shares of Neurocrine Biosciences by 11.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,738 shares of the company's stock valued at $200,000 after acquiring an additional 185 shares in the last quarter. CWM LLC raised its holdings in shares of Neurocrine Biosciences by 15.1% during the third quarter. CWM LLC now owns 7,884 shares of the company's stock valued at $908,000 after purchasing an additional 1,035 shares during the period. Finally, Perpetual Ltd grew its stake in Neurocrine Biosciences by 96.6% in the third quarter. Perpetual Ltd now owns 12,560 shares of the company's stock valued at $1,447,000 after acquiring an additional 6,170 shares during the period. Institutional investors own 92.59% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.